SS Innovations International (NASDAQ: SSII) reported a 79% increase in cumulative procedures performed with its SSi Mantra surgical robotic system, reaching 14,103 as of Sept. 8, 2026, up from 7,885 at the end of 2025. The company also said its installed base grew 42% to 238 systems from 168, according to a press release detailing the expansion and utilization of the platform.
The SSi Mantra is now installed in 12 countries, with approximately 1,500 physicians trained on the system. It has been used for more than 170 types of surgical procedures, underscoring its versatility and growing acceptance among surgeons. Recent international milestones include the launch of robotic cardiac surgery in Colombia, the installation of the first SSi Mantra in Sri Lanka, and the first telesurgery within the Philippines.
SS Innovations also highlighted 258 cumulative pediatric robotic surgeries and 188 robotic telesurgeries as of Aug. 31, including a more than 13,600-mile telesurgery between Colombia and India. In August, five SSi Mantra systems were used to complete 50 robotic general surgery procedures in a single day in India.
Looking ahead, the company expects the U.S. Food and Drug Administration to complete its review of the SSi Mantra 510(k) premarket notification by the end of the first quarter of 2027. It also believes European Union CE marking certification can be obtained by year-end 2026. These regulatory milestones could significantly expand the addressable market for SS Innovations, particularly in the United States and Europe, where robotic surgery is widely adopted but often dominated by costly systems.
The growth in procedures and installations matters because it demonstrates that SS Innovations’ strategy to make robotic surgery affordable and accessible is gaining traction. The company, an American firm headquartered in India, develops the SSi Mantra system and the SSi Mudra suite of surgical instruments, which support a variety of procedures including cardiac surgery. Its focus on cost-effective solutions could help hospitals in emerging markets and underserved regions adopt robotic surgery, potentially improving patient outcomes and expanding access to minimally invasive techniques.
For investors, the update provides key performance indicators that suggest strong momentum. The 79% jump in procedures and 42% increase in installed systems indicate rising utilization and adoption. The pending FDA clearance and expected CE marking are critical catalysts that could further accelerate growth. However, the company notes forward-looking statements are subject to risks and uncertainties, and actual results may differ materially. More information is available in the full report at https://ibn.fm/DJILj, and the latest news and updates relating to SSII can be found in the company’s newsroom at https://ibn.fm/SSII.
Overall, the announcement highlights SS Innovations’ progress in scaling its robotic surgery platform globally. As the company awaits regulatory decisions in major markets, its ability to demonstrate real-world adoption and procedural diversity will be crucial in competing with established players. The coming year could be pivotal if the FDA and EU certifications are secured, potentially opening new avenues for growth and furthering the mission of making robotic surgery more accessible.
